Tryptamin studier 2025 2026 overblik

Tryptamine Studies 2025-2026: Pharmacology Data

Current Research Landscape – From Receptor Binding to Clinical Trials

Tryptaminforskningen oplever i 2025/2026 et vendepunkt. Nye receptorbindingsdata, kliniske psilocybinstudier, første farmakologiske karakteriseringer af propionyloxytryptaminer. Her er den aktuelle forskningsstatus – med fokus på 4-Pro-MET og dets position i det videnskabelige landkort. Kildebaseret på: peer-reviewed studier, PubChem, PsychonautWiki og community-data.

Indholdsfortegnelse

Indlæser...

Vigtige publicerede studier

Den vigtigste publikation for 4-Pro-MET-forskning: Glatfelter et al. (2023), publiceret i ACS Pharmacology & Translational Science (PMC10111620). Studiet leverer det første receptorbindingsprofil for 4-PrO-DMT – det nærmeste analogon til 4-Pro-MET (samme propionyloxy-ester, men N,N-dimethyl i stedet for N-methyl-N-ethyl).

Bindingsaffiniteter for 4-PrO-DMT (Ki-værdier i nM)

5-HT2B: 17 nM (meget høj affinitet)
5-HT1: 54 nM (høj affinitet)
5-HT2a: 73 nM (høj affinitet)
5-HT2C: 228 nM (moderat affinitet)
5-HT2A: 336 nM (moderat affinitet) – den 'psykedeliske receptor'
5-HT2A: 396 nM (moderat affinitet) – anxiolytisk
Kappa-opioid (KOR): 4.745 nM – enestående blandt de testede tryptaminer

Funktionel aktivitet

Ved 5-HT2A viste 4-PrO-DMT en efficacy på 93–104% (næsten fuldagonisme) med EC50 = 3,93 nM. Næsten fuldstændig receptoraktivering – en forudsætning for robuste psykedeliske effekter. 5-HT2A-antagonisten M100907 blokerede fuldstændigt Head-Twitch-Response hos mus (ED50: 0,31 mg/kg s.c.), hvilket bekræfter den 5-HT2A-medierede mekanisme.

KOR-binding: En særlig egenskab

4-PrO-DMT var det eneste testede 4-substituerede tryptamin med påviselig kappa-opioidreceptoraffinitet (Ki = 4.745 nM). KOR-aktivering er associeret med dysforiske effekter – ved denne lave affinitet forbliver den kliniske relevans dog uklar. Om 4-Pro-MET (N-Me-N-Et i stedet for N,N-DiMe) viser tilsvarende KOR-binding? Et åbent forskningsspørgsmål.

For 4-HO-MET (den aktive metabolit af 4-Pro-MET) foreligger to retsmedicinsk relevante studier:

In vitro-metabolisme (Forensic Science International, 2018)

Med menneskelige levermikrosomer blev 12 metabolitter af 4-HO-MET identificeret in vitro. 4 af dem lod sig påvise i menneskelig urin. Metaboliseringen omfatter fase I-reaktioner (hydroxylering, O-demethylering, N-dealkylering) og fase II-konjugering (glucuronidering). Central for retskemisk analyse – disse markører definerer, hvad der søges i biologiske prøver.

Klinisk toksikologitilfælde (Journal of Analytical Toxicology, 2021)

Et ikke-fatalt intoksikationstilfælde med 4-HO-MET: Plasmakoncentration 193 ng/mL. Påvisning kun via blodplasmaanalyse ved hjælp af LC-MS/MS – standard-immunoassays (urin-hurtigtest) detekterede ikke substansen. Tryptaminer kræver specialiseret analytik. For forskere betyder det: 4-HO-MET er retskemisk påviseligt, men ikke via rutineanalyser.

No clinical trials exist for 4-Pro-MET. But the broader tryptamine landscape gives useful context. As of early 2026, over 15 Phase II/III psilocybin trials are active or completed. COMPASS Pathways' Phase IIb trial for treatment-resistant depression (n=233), published in the New England Journal of Medicine, showed significant efficacy at 25 mg dose. Usona Institute's Phase II trial for major depressive disorder landed similar results. The money followed: the global psychedelic therapy market is projected to reach $10+ billion by 2030.

One thing stands out, though. Every current clinical program uses psilocybin or synthetic psilocin – not novel tryptamines like 4-Pro-MET. Getting a new tryptamine through independent Phase I-III development would cost $50-100+ million and take 5-10+ years. That's a high bar.

Juridisk meddelelse

Dies ist ein Beispiel-Infotext. Hier können Sie wichtige Hinweise für Ihre Leser hinterlegen.

Lab-Tested 4-Pro-MET

Quality-verified – CoA included – EU shipping

Se produkter

Frequently Asked Questions

What is the most important study for 4-Pro-MET research?

Two studies stand out: (1) Glatfelter et al. (2023) in ACS Pharmacology & Translational Science, which characterized receptor binding profiles for 4-PrO-DMT – the closest studied analogue – including 5-HT2A affinity, functional activity, and mouse behavioral data. (2) Jones et al. (2024) in Frontiers in Psychiatry, which provided the first in vivo proof that 4-AcO-DMT functions as a prodrug of psilocin (~70% bioavailability), strongly supporting the prodrug hypothesis for all 4-acyloxy tryptamines including 4-Pro-MET.

Are there any clinical trials for 4-Pro-MET?

No. As of April 2026, no clinical trials exist for 4-Pro-MET. The compound first appeared as a research chemical in late 2025. All clinical psychedelic trials use psilocybin or synthetic psilocin. Independent clinical development for a novel tryptamine would require $50-100M+ and 5-10+ years.

What did Glatfelter et al. find about 4-PrO-DMT?

Key findings: 5-HT2A binding affinity Ki = 336 nM, functional EC50 = 3-93 nM with 93-104% efficacy, head-twitch response ED50 = 0.31 mg/kg in mice, and unique kappa-opioid receptor affinity (Ki = 4,745 nM) not seen in other 4-substituted tryptamines tested.

How many psilocybin clinical trials are running?

Over 15 Phase II/III psilocybin trials are active or completed as of 2026, targeting treatment-resistant depression, major depression, PTSD, alcohol use disorder, anorexia, and end-of-life anxiety. Major programs include COMPASS Pathways and Usona Institute.

What are the key research gaps for 4-Pro-MET?

No human pharmacokinetic data, no LD50, no long-term safety data, no confirmed prodrug conversion in vivo, unknown 5-HT2B cardiac risk for chronic use, no receptor binding data for 4-Pro-MET itself (only analogues), and no clinical efficacy or safety data.